Grow Pharma CEO sees post-Brexit opportunity for medical cannabis

Imports and exports have changed since Brexit – including the traffic in pharmaceuticals between the EU and the UK. Grow Pharma’s CEO Pierre Van Weperen chats to Proactive London about how the company’s partner, IPS Pharma, will produce the cannabis oils at its certified production facility in Surrey.

Not only will this ease import and export problems at EU/UK borders but it will also save money. Grow Pharma said it has started trials to extract cannabis-based medical products in the UK, making it only the second company to have done so after GW Pharmaceuticals (NASDAQ:GWPH). Privately-owned distributor Grow, part of , said it is attempting to replicate and distribute cannabis-based medicinal products (CBMPs) for patients experiencing Brexit disruption to supplies.